Tirzepatide research: what the trials measured and what they missed

The short version

Tirzepatide is one of the most studied new drugs of the past decade. The headline results: in type 2 diabetes, it reduces HbA1c (a 3-month blood sugar average) by around 2.0-2.3 percentage points — consistently outperforming semaglutide in the only direct head-to-head comparison in type 2 diabetes (SURPASS-2). In obesity without diabetes, it cut body weight by an average of 15-21% over 72 weeks (SURMOUNT-1), again outperforming semaglutide in a direct comparison (SURMOUNT-5). New data show effects on heart failure with preserved ejection fraction, sleep apnea, and a serious form of fatty liver disease. The drug works on two gut hormone receptors at once (GIP and GLP-1), which appears to explain its larger effects compared to drugs targeting only GLP-1. The main open questions: weight regain when the drug is stopped, lean-mass loss alongside fat loss, and some safety signals (gallbladder disease, the unconfirmed thyroid C-cell animal data) that warrant monitoring.

Tirzepatide mechanism of action

Tirzepatide activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a single 39-amino-acid molecule ^[1][2].

GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones — gut-derived peptides released after a meal that amplify insulin secretion from the pancreas in a glucose-dependent way. Both also have receptors in the central nervous system and adipose tissue involved in appetite and fat metabolism.

In vitro receptor characterisation found tirzepatide is an 'imbalanced' dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor. It also exhibits biased GLP-1 receptor signalling that favours cAMP generation over beta-arrestin recruitment (meaning less receptor internalisation than native GLP-1) — a property proposed to enhance insulin secretion efficiency ^[2]. In primary islet experiments, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide ^[2].

The net result of dual receptor activation: enhanced glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced appetite and food intake, and weight reduction — all larger in trials than selective GLP-1 agonism alone.

A mechanistic substudy in people with type 2 diabetes confirmed that tirzepatide improved both beta-cell function (the pancreas's capacity to make insulin) and insulin sensitivity (how well cells respond to it) ^[9].

SURPASS trials: type 2 diabetes

SURPASS-1 (monotherapy): In adults with type 2 diabetes inadequately controlled by diet and exercise, once-weekly tirzepatide produced substantial dose-dependent reductions in HbA1c and body weight versus placebo over 40 weeks ^[8].

SURPASS-2 (vs semaglutide, n=1,879, 40 weeks): Once-weekly tirzepatide 5, 10, or 15 mg versus semaglutide 1 mg. HbA1c reduction: -2.01, -2.24, and -2.30 percentage points versus -1.86 percentage points. Tirzepatide was noninferior and superior at all three doses. Body weight treatment differences: -1.9, -3.6, and -5.5 kg in favour of tirzepatide. Most common adverse events were gastrointestinal and mostly mild to moderate ^[3].

SURPASS-3 (vs insulin degludec, add-on to metformin ± SGLT2 inhibitor): Once-weekly tirzepatide versus once-daily insulin degludec. Tirzepatide produced greater HbA1c reduction and greater weight loss ^[10].

SURPASS-5 (add-on to insulin glargine): In type 2 diabetes inadequately controlled on insulin glargine, adding tirzepatide significantly improved glycaemic control and reduced body weight versus placebo ^[11].

Beta-cell function and insulin sensitivity (mechanistic substudy): Tirzepatide improved markers of beta-cell function and insulin sensitivity in people with type 2 diabetes — mechanistically consistent with the dual incretin mechanism ^[9].

The full Tirzepatide references list covers all SURPASS trial citations with DOIs and PubMed links.

SURMOUNT trials: obesity and beyond

SURMOUNT-1 (obesity without type 2 diabetes, n=2,539, 72 weeks): Once-weekly tirzepatide 5, 10, or 15 mg versus placebo. Mean weight change at week 72: -15.0%, -19.5%, and -20.9% versus -3.1% with placebo. 63% of participants at 15 mg lost ≥20% of body weight. Most common adverse events were gastrointestinal and mostly mild to moderate during dose escalation ^[4].

SURMOUNT-5 (head-to-head vs semaglutide in obesity, n=751, 72 weeks): Maximum tolerated dose of tirzepatide (10 or 15 mg) versus maximum tolerated dose of semaglutide (1.7 or 2.4 mg). Least-squares mean weight change: -20.2% versus -13.7% (P<0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching ≥10/15/20/25% weight loss ^[5].

SURMOUNT-4 (maintenance, withdrawal randomisation): Participants who lost weight on tirzepatide were re-randomised to continue or switch to placebo. Those continuing tirzepatide maintained or increased their weight loss; those switched to placebo regained. This supports chronic rather than short-course use ^[25].

SUMMIT (heart failure with preserved ejection fraction and obesity): Tirzepatide versus placebo in obesity-related HFpEF (heart failure where the pumping fraction remains normal). The trial met its primary composite endpoint ^[32]. A cardiac MRI substudy found tirzepatide reduced left ventricular mass by 11 g (95% CI -19 to -4 g) and paracardiac adipose tissue by 45 mL versus placebo ^[35].

SURMOUNT-OSA (obstructive sleep apnea and obesity): Tirzepatide versus placebo in adults with obstructive sleep apnea and obesity. The trial met its primary endpoint — tirzepatide is FDA-approved for this indication ^[33].

SYNERGY-NASH (metabolic dysfunction-associated steatohepatitis): Tirzepatide versus placebo in MASH (formerly NASH, a form of fatty liver disease involving inflammation and fibrosis). The trial met its primary histological endpoint ^[34].

Tirzepatide results: a summary of the evidence quality

The tirzepatide evidence base is exceptionally strong by drug-development standards. Multiple large, well-powered randomised controlled trials across different populations show consistent dose-response glycaemic and weight results.

Honest caveats: much of the highest-quality evidence is sponsor-funded (standard for a novel drug, but worth noting). Weight regain after discontinuation is well-documented. The lean-mass loss magnitude alongside fat loss remains under investigation for functional implications ^[12][13][24]. The thyroid C-cell signal from rodents has not been confirmed in humans but has not been refuted — the label contraindication for a family history of medullary thyroid carcinoma or MEN-2 stands ^[16][17].

The gallbladder and biliary disease signal is consistent across multiple meta-analyses and is the most clinically actionable safety concern outside GI tolerability ^[18][19].

See Tirzepatide references for the full citation list.